Fundraising Fox
Prelude Therapeutics
NASDAQ: PRLDUnicorn · $2.8BNewark, US · Founded 2016 · Delaware corporation · 101 employees on LinkedIn · 2 known investors
Find your way into Prelude Therapeutics
Sign up to see every warm intro you have to Prelude Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Prelude Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors. It also applies targeted protein degradation expertise to develop next-generation degrader antibody conjugates (DACs).
Founders & leadership
Prelude Therapeutics was founded in 2016 by Krishna Vaddi.
Board
Investors · 2
How we know: OrbiMed's portfolio page · the S-1 prospectus · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$115M disclosed across 4 rounds · 2016–2020
▶$50MraisedAug 2020 · 7 investors · BiotechnologyRule 506(b)
- David BonitaDirector
- Victor SandorDirector
- Peggy ScherleExecutive Officer
- Christopher PierceExecutive Officer
- Deborah MorosiniExecutive Officer
- Krishna VaddiExecutive Officer, Director
- Brian PiperExecutive Officer
- Mardi C. DierDirector
- Paul FriedmanDirector
- Kelvin NeuDirector
- David MauroExecutive Officer
- Andrew CombsExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$30MraisedJun 2019 · 6 investors · BiotechnologyRule 506(b)
- Krishna VaddiExecutive Officer, Director
- David MauroExecutive Officer
- Peggy ScherleExecutive Officer
- Kelvin NeuDirector
- David BonitaDirector
- Paul FriedmanDirector
- Offering amount
- $60M
- Amount sold
- $30M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$30MraisedAug 2018 · 7 investors · BiotechnologyRule 506(b)
- Juan LuengoExecutive Officer
- David BonitaDirector
- Paul FriedmanDirector
- Kelvin NeuDirector
- Krishna VaddiExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$5MraisedJul 2016 · 8 investors · BiotechnologyRule 506(b)
- Krishna VaddiExecutive Officer, Director
- Paul FriedmanDirector
- David BonitaDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
Companies working in the same space as Prelude Therapeutics.
Frequently asked questions
- What does Prelude Therapeutics do?
- Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors. It also applies targeted protein degradation expertise to develop next-generation degrader antibody conjugates (DACs).
- Who founded Prelude Therapeutics?
- Prelude Therapeutics was founded by Krishna Vaddi in 2016.
- Who are Prelude Therapeutics's investors?
- Prelude Therapeutics's investors include OrbiMed, The Innovation Space.
- How much funding has Prelude Therapeutics raised?
- Prelude Therapeutics has disclosed $115M raised across 4 rounds.
- Where is Prelude Therapeutics headquartered?
- Prelude Therapeutics is headquartered in Newark, US.